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Abstract
Background: Shiga toxin-producing Escherichia coli (STEC) is an important cause of bloody diarrhoea (BD), non-bloody
diarrhoea (NBD) and the haemolytic uraemic syndrome (HUS). In Argentina and New Zealand, the most prevalent STEC
serotype is O157:H7, which is responsible for the majority of HUS cases. In Australia, on the other hand, STEC O157:H7
is associated with a minority of HUS cases. The main aims of this study were to compare the phenotypic and genotypic
characteristics of STEC O157 strains isolated between 1993 and 1996 from humans in Argentina, Australia and New
Zealand, and to establish their clonal relatedness.
Results: Seventy-three O157 STEC strains, isolated from HUS (n = 36), BD (n = 20), NBD (n = 10), or unspecified
conditions (n = 7) in Argentina, Australia and New Zealand, were analysed. The strains were confirmed to be E. coli O157
by biochemical tests and serotyping. A multiplex polymerase chain reaction (PCR) was used to amplify the stx1, stx2 and
rfbO157 genes and a genotyping method based on PCR-RFLP was used to determine stx1 and stx2 variants. This analysis
revealed that the most frequent stx genotypes were stx2/stx2c (vh-a) (91%) in Argentina, stx2 (89%) in New Zealand, and
stx1/stx2 (30%) in Australia. No stx1-postive strains were identified in Argentina or New Zealand. All strains harboured
the eae gene and 72 strains produced enterohaemolysin (EHEC-Hly). The clonal relatedness of strains was investigated
by phage typing and pulsed-field gel electrophoresis (PFGE). The most frequent phage types (PT) identified in Argentinian,
Australian, and New Zealand strains were PT49 (n = 12), PT14 (n = 9), and PT2 (n = 15), respectively. Forty-six different
patterns were obtained by XbaI-PFGE; 37 strains were grouped in 10 clusters and 36 strains showed unique patterns.
Most clusters could be further subdivided by BlnI-PFGE.
Conclusion: STEC O157 strains isolated in Argentina, Australia, and New Zealand differed from each other in terms
of stx-genotype and phage type. Additionally, no common PFGE patterns were found in strains isolated in the three
countries. International collaborative studies of the type reported here are needed to detect and monitor potentially
hypervirulent STEC clones.
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Background
Shiga toxin-producing Escherichia coli (STEC) is an impor-
tant emerging pathogen which can cause bloody diar-
rhoea (BD), non-bloody diarrhoea (NBD) and the
haemolytic uraemic syndrome (HUS). The ability of STEC
strains to cause severe disease in humans is related to their
capacity to secrete Shiga toxins, Stx1 and Stx2, and vari-
ants of these toxins [1,2]. Another virulence-associated
factor of most STEC isolates associated with severe disease
is intimin, a 94-kDa outer membrane protein, which is
encoded by the eae gene on a ca. 34-kb chromosomal
pathogenicity island termed the locus of enterocyte efface-
ment (LEE). This locus is associated with the intimate
adherence of E. coli to epithelial cells, initiation of host
signal transduction pathways, and the formation of
attaching-and-effacing intestinal lesions [3]. In addition,
most STEC strains associated with BD or HUS produce an
enterohaemolysin (EHEC-Hly), encoded by a plasmid-
borne gene, known as ehxA [4].
Argentina has a high incidence of HUS: 13.9 cases per
100,000 children younger than 5 years old were reported
in 2005 [5]. This rate is 10-fold higher than in other
industrialised countries [6]. In Argentina STEC is the pri-
mary aetiological agent of HUS, and E. coli O157:H7 is the
predominant serotype isolated [7]. In Australia and New
Zealand the annual incidence of HUS, determined
through active surveillance, is approximately 1.0 to 1.3
per 100,000 children less than 5 years old [8]. Interest-
ingly, the predominant STEC serotypes associated with
HUS in these two countries differs. Whereas in New Zea-
land O157 strains make up around half of the isolates, in
Australia serotype O111 STEC account for most HUS
cases, with O157 associated with fewer than 20% [8,9].
The reasons for these differences are not known.
The aims of this study were to compare the phenotypic
and genotypic characteristics of STEC O157 strains iso-
lated from humans in Argentina, Australia and New Zea-
land during the period 1993–1996, and to establish the
genetic diversity and clonal relatedness among the strains
isolated in these three countries. The rationale for under-
taking this study was based upon national and interna-
tional concerns that modern centralised and rapid food
distribution systems in these countries together with
recent increases in the volume of food trade internation-
ally and the enormous increase in global travel could
allow the unfettered, and undetected, worldwide spread
of virulent clones of STEC O157.
Results
Of the 73 strains examined (35 from Argentina, 20 from
Australia and 18 from New Zealand), 36 were isolated
from HUS cases, 20 from BD cases, and 10 from NBD
cases. The clinical origin of 7 strains was not specified
(Table 1). All strains were confirmed as E. coli O157, were
cytotoxic for Vero cells, and carried the genes encoding
intimin and fliCH7, even though several were non-motile
in vitro, and were typed as O157:H- (data not shown).
Production of enterohaemolysin was observed in 72
(98.6%) of 73 strains, in agreement with the polymerase
chain reaction (PCR) results.
PCR-restriction fragment length polymorphism (RFLP)
genotyping of the 73 O157 STEC strains showed that 35
(48%) strains harboured stx2 and stx2c (vh-a), 22 (30%) car-
ried only stx2, 6 (8%) carried stx1 and stx2, 4 (5%) carried
stx1 and stx2c (vh-a), 3 (4%) carried only stx2c (vh-a), 2 (3%)
carried only stx1 and 1 (1%) carried stx1 and stx2-UT (Table
2). The most frequent stx genotypes were stx2 and stx2c (vh-
a) (32/35; 91%) in Argentina, stx1 and stx2 (6/20; 30%) in
Australia, and stx2(16/18; 89%) in New Zealand. stx2 was
the only stx-genotype found in all 3 countries. No stx1-
positive strains were obtained from patients in Argentina
or New Zealand, compared with 13 of 20 from Australia
(P < 0.0001; Fisher's exact test, two-tailed). Of the 13 stx1-
positive strains isolated in Australia, however, 11 were
also positive for stx2 or stx2c. Notwithstanding these differ-
ence in toxin profile, there was no significant association
between stx genotype and the clinical presentation of the
patient from whom the strain was obtained (Table 3; P >
0.5, Kruskal-Wallis test).
Table 1: Clinical presentation of patients in Argentina, Australia, and New Zealand from whom STEC O157 strains were isolated 
between 1993 and 1996.
No. (%) of strains from:
Clinical presentation Argentina Australia New Zealand
Haemolytic uraemic syndrome 22 (63) 6 (30) 8 (44)
Bloody diarrhoea 10 (29) 3 (15) 7 (39)
Non-bloody diarrhoea 3 (9) 5 (25) 2 (22)
Non-specific 0 (0) 6 (30) 1 (6)
Total 35 (100) 20 (100) 18 (100)BMC Microbiology 2008, 8:46 http://www.biomedcentral.com/1471-2180/8/46
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The most frequent phage types (PT) identified in Argen-
tina, Australia, and New Zealand were PT49 (12/35;
34%), PT14 (9/20; 45%), and PT2 (15/18; 83%), respec-
tively (Table 4). PT4 was the only PT found in all 3 coun-
tries with frequencies of 31% (11/35) in Argentina; 15%
(3/20) in Australia, and 11% (2/18) in New Zealand.
There was no significant association between phage type
and the clinical presentation of the patient from whom
the strain was obtained (P > 0.5, Kruskal-Wallis test).
Pulsed-field gel electrophoresis (PFGE) of XbaI-digested
genomic DNA was used to subtype all 73 STEC O157
strains, generating 46 distinct PFGE patterns with 16–24
discernible fragments, ranging from approximately 32 to
730 kb in size. Twenty-one patterns were identified
amongst 35 strains isolated in Argentina, 14 patterns in 20
strains from Australia, and 11 patterns in 18 strains from
New Zealand.
Ten clusters contained isolates with indistinguishable
XbaI-PFGE profiles (Figure 1). These were cluster I (3
strains from Argentina); cluster II (3 strains from Aus-
tralia); cluster III (2 strains from Argentina); cluster IV (5
strains from Argentina); cluster V (2 strains from New Zea-
land); cluster VI (8 strains from Argentina); cluster VII (2
strains from New Zealand); cluster VIII (4 strains from
New Zealand); cluster IX (3 strains from New Zealand);
and cluster X (5 strains from Australia). To refine the clus-
ter analysis further, we determined the BlnI-PFGE profile
of each isolate. This revealed that most strains with iden-
tical  XbaI-PFGE pattern could be discerned from each
other by restriction with a second enzyme (Table 5). Some
clusters could also be split by using phage typing and stx
genotyping (Table 5). Only two clusters, II (3 strains) and
X (5 strains), both from Australia, were indistinguishable
by XbaI- and BlnI-PFGE, phage typing and stx-genotyping,
indicating that these were probable clones.
In Argentina, the predominant XbaI-PFGE patterns were
AREXHX01-0011 (cluster VI, 8 strains), AREXHX01-0022
(cluster IV, 5 strains), AREXHX01-0013 (cluster I, 3
strains) and AREXHX01-0014 (cluster III, strains). The
eight strains in cluster VI were recovered from three HUS
cases and one BD case in 1993. and from two HUS cases
and two BD cases in 1996. All of these isolates carried stx2
and stx2c (vh-a), except one strain isolated from a patient
with HUS which carried stx2 only. Seven strains belonged
to PT4, and one to PT26. Four of the five strains in cluster
IV carried stx2 and stx2c (vh-a). Four strains in this cluster
were isolated from one case each of NBD, BD, and two of
HUS in 1996. Three of these strains belonged to PT49, and
one to PT4. The three stx2/stx2c (vh-a) PT49 strains in this
cluster showed the same pattern on BlnI-PFGE and are
likely to be a clone. The remaining strain in this cluster
carried stx2, belonged to PT49, and was recovered from an
Table 2: stx genotype of STEC O157 strains isolated between 
1993 and 1996 from humans in Argentina, Australia and New 
Zealand.
No. (%) of strains from:
stx genotype Argentina Australia New Zealand
stx1 02  ( 1 0 ) 0
stx2 3 (9) 3 (15) 16 (89)
stx2c (vh-a) 0 1 (5) 2 (11)
stx1/stx2 06  ( 3 0 ) 0
stx1/stx2c (vh-a) 04  ( 2 0 ) 0
stx1/stx2-UT 01  ( 5 ) 0
stx2/stx2c (vh-a) 32 (91) 3 (15) 0
Total 35 (100) 20 (100) 18 (100)
Table 3: Distribution of STEC O157 strains isolated from 
humans with haemolytic uraemic syndrome (HUS), bloody 
diarrhoea (BD), non-bloody diarrhoea (NBD) or other non-
specified conditions (NS) according to stx genotype.
No. (%) of strains from patients with :
stx genotype HUS BD NBD NS
stx1 0 0 2 (20) 0
stx2 12 (33) 6 (30) 3 (30) 1 (14)
stx2c (vh-a) 0 2 (10) 1 (10) 0
stx1/stx2 1 (3) 0 0 5 (71)
stx1/stx2c (vh-a) 1 (3) 2 (10) 1 (10) 0
stx1/stx2-UT 000 1  ( 1 4 )
stx2/stx2c (vh-a) 22 (61) 10 (50) 3 (30) 0
Total 36 (100) 20 (100) 10 (100) 7 (100)
Table 4: Phage type of STEC O157 strains isolated between 1993 
and 1996 from humans in Argentina, Australia and New 
Zealand.
No. (%) of strains from:
Phage type Argentina Australia New Zealand
10 1  ( 5 ) 0
2 8 (23) 0 15 (83)
4 11 (31) 3 (15) 2 (11)
14 1 (3) 9 (45) 0
21 0 1 (5) 0
26 2 (6) 1 (5) 0
32 0 0 1 (6)
49 12 (34) 0 0
54 0 3 (15) 0
Untypeable 1 (3) 2 (10) 0
Total 35 (100) 20 (100) 18 (100)BMC Microbiology 2008, 8:46 http://www.biomedcentral.com/1471-2180/8/46
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Clonal relationship of 73 STEC O157 strains isolated between 1993 and 1996 from humans in Argentina, Australia, and New  Zealand Figure 1
Clonal relationship of 73 STEC O157 strains isolated between 1993 and 1996 from humans in Argentina, Aus-
tralia, and New Zealand.BMC Microbiology 2008, 8:46 http://www.biomedcentral.com/1471-2180/8/46
Page 5 of 8
(page number not for citation purposes)
HUS case in 1995. The three strains in cluster I carried stx2
and stx2c (vh-a) and were isolated from a BD case in 1993,
and from a BD and a HUS case in 1996. All three belonged
to different PTs (PT49, PT14, and PT-UT). The two strains
in cluster III, carried stx2 and stx2c (vh-a), belonged to PT49
and were isolated from a BD case in 1993, and an HUS
case in 1995.
In Australia, the predominant XbaI-PFGE patterns were
AUEXHX01-0013 (cluster X, 5 strains), and AUEXHX01-
0014 (cluster II, 3 strains). All five strains in cluster X car-
ried stx1 and stx2, belonged to PT14, and were isolated in
1996 from one HUS case, two contacts of this case and
from two individuals with an unspecified disease other
than HUS or diarrhoea. These strains also showed the
same BlnI-PFGE pattern (Table 5). All three strains in clus-
ter II carried stx2 and stx2c (vh-a), belonged to PT54 and were
isolated from HUS cases in 1996. The strains were also
indistinguishable by BlnI-PFGE. The only enterohaemo-
lysin-negative strain in this study carried stx2  alone,
belonged to PT21 and was isolated from a HUS case in
1995.
In New Zealand, the predominant XbaI-PFGE patterns
were NZEXHX01-0005 (cluster VIII, 4 strains),
NZEXHX01-0003 (cluster IX, 3 strains), NZEXHX01-0010
(cluster V, 2 strains), and NZEXHX01-0006 (cluster VII, 2
strains). The four strains in cluster VIII were isolated from
BD cases in 1994, 1995 and 1996, and from a HUS case in
1994. The three strains in cluster IX were obtained from
two HUS cases in 1993 and one case of BD in 1994. The
two strains in cluster V were isolated from BD cases in
1996, and the two strains in cluster VII were isolated from
an HUS case in 1995 and a NBD case in 1996. All 11
strains harboured stx2  and were the same phage type
(PT2).
Discussion
This study revealed differences in the stx genotype, phage
type and PFGE profiles of clinically-significant STEC
O157 strains isolated from humans in Argentina, Aus-
tralia and New Zealand. Strains that possessed both stx1
and stx2 were relatively more prevalent in Australia as is
the case in the USA [10], Japan [11] and Chile [12],
amongst others. On the other hand, the relatively high
prevalence of stx2-positive strains in New Zealand resem-
bles the toxin profile of STEC O157 in Western Europe
[13,14]. In Argentina, all isolates were either stx2 or and
stx2/stx2c (vh-a), with stx2/stx2c (vh-a) strains accounting for
more than 90% of isolates. This highly virulent genotype
has been described by Nishikawa et al. [15] as being asso-
ciated with severe human disease. The high frequency of
Table 5: Discrimination of STEC O157 strains within XbaI-PFGE clusters by phage type, stx genotype and BlnI-PFGE.
Cluster/No. of XbaI-PFGE No. of strains Phage type stx genotype BlnI-PFGE pattern
I (AREXHX01-0013) 1 14 stx2 and stx2c (vh-a) AREXHA26-0013
14 9 stx2 and stx2c (vh-a) AREXHA26-0015
1U T stx2 and stx2c (vh-a) AREXHA26-0024
II (AUEXHX01-0014) 3 54 stx2 and stx2c (vh-a) AUEXHA26-0002
III (AREXHX01-0014) 1 49 stx2 and stx2c (vh-a) AREXHA26-0018
14 9 stx2 and stx2c (vh-a) AREXHA26-0015
IV (AREXHX01-0022) 3 49 stx2 and stx2c (vh-a) AREXHA26-0015
14 stx2 and stx2c (vh-a) AREXHA26-0015
14 9 stx2 AREXHA26-0019
V (NZEXHX01-0010) 1 2 stx2 NZEXHA26-0003
12 stx2 NZEXHA26-0007
VI (AREXHX01-0011) 2 4 stx2 and stx2c (vh-a) AREXHA26-0008
14 stx2 and stx2c (vh-a) AREXHA26-0031
12 6 stx2 and stx2c (vh-a) AREXHA26-0011
14 stx2 and stx2c (vh-a) AREXHA26-0023
14 stx2 and stx2c (vh-a) AREXHA26-0022
14 stx2 and stx2c (vh-a) AREXHA26-0009
14 stx2 AREXHA26-0025
VII (NZEXHX01-0006) 1 2 stx2 NZEXHA26-0005
12 stx2 NZEXHA26-0004
VIII (NZEXHX01-0005) 2 2 stx2 NZEXHA26-0001
12 stx2 NZEXHA26-0002
12 stx2 NZEXHA26-0006
IX (NZEXHX01-0003) 1 2 stx2 NZEXHA26-0001
12 stx2 NZEXHA26-0002
12 stx2 NZEXHA26-0003
X (AUEXHX01-0013) 5 14 stx1 and stx2 AUEXHA26-0001BMC Microbiology 2008, 8:46 http://www.biomedcentral.com/1471-2180/8/46
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this toxin profile in isolates from Argentina, and that of
Stx2-producing STEC in New Zealand, which are also
reportedly more virulent than other strains [16], com-
pared with Australia (Table 2), may account in part for the
relatively low frequency of severe infection with STEC
O157 in Australia compared with the other countries. Our
finding that stx  profile was not significantly associated
with clinical presentation, may have been due to a sam-
pling error, in that isolates from the sickest patients are
more likely to be sent to reference laboratories for charac-
terisation.
At least 90 phage types have been reported for STEC O157
[17], but only four of these (PT2, PT4, PT14, and PT49)
accounted for 84% of the strains analysed in this study. In
Europe and Canada, PT2, PT4, PT8, PT14, PT21, PT32,
and PT54 account for the majority (> 75%) of STEC O157
strains obtained from humans [18]. Six of these PTs (PT2,
PT4, PT14, PT21, PT32, and PT54), were identified in the
present study, but only PT4 occurred in all three countries.
PT2 and PT8 predominate among human strains of STEC
O157 in Spain, Belgium, Finland, Germany, Italy, Eng-
land and Scotland [17,19]. In our study, PT2 was predom-
inant in New Zealand strains, and also was identified
among the Argentinian strains, but not in Australian
strains. PT8 was not identified in this study. PT14, pre-
dominant in Canada [17], was identified in Argentinian
and Australian strains, but not in those from New Zea-
land. PT49 and PT4 were common in Argentina, but
absent (PT49) or infrequent (PT4) in Australia and New
Zealand.
PFGE is the ''gold standard'' of genetic fingerprinting
methods for E. coli O157 and is particularly useful for
tracking outbreak strains [20]. In this study a high degree
of diversity was observed among the strains analysed by
this technique. No common XbaI-PFGE pattern was found
in strains isolated in Argentina, Australia or New Zealand.
However, different clusters were detected in each country.
The predominant XbaI-PFGE patterns were: AREXHX01-
0011 (8 strains) in Argentina, AUEXHX01-0013 (5
strains) in Australia and NZEXHX01-0005 (4 strains) in
New Zealand. The EXHX01-0011 and EXHX01-0022 pat-
terns that were frequent in this study are common within
the Argentinian Database, comprising 30% of the STEC
O157 isolates detected in different regions of Argentina
during the last 10 years [5]. AREXHX01-0011 is indistin-
guishable from EXHX01-0047, the second most common
pattern in the US national database, accounting for
approximately 4.6% of strains. The most recent multi-
state outbreak with a strain of this pattern occurred in
2003 and was linked to beef, resulting in a food recall
[21].
All but two of the XbaI-PFGE clusters could be subdivided
by one or more of stx genotyping, phage typing and BlnI-
PFGE (Table 5). Those which could not be subdivided in
this way included three strains that were epidemiologi-
cally related, and others that may have been responsible
for small, undetected community outbreaks of infection.
In the absence of pertinent data about the patients from
whom these strains were obtained, however, we were una-
ble to test this hypothesis.
Conclusion
The 73 STEC O157 strains isolated between 1993 and
1996 from symptomatic humans in Argentina, Australia
and New Zealand differed in terms of stx-genotype and
phage type. No common XbaI-PFGE pattern was found in
the strains isolated in the three countries, indicating that
there up until 1996 there was little spread of STEC O157
between them. Most isolates with common XbaI-PFGE
patterns could be distinguished form each other by stx
genotyping, phage typing or BlnI-PFGE. By conducting
international collaborative studies, using standardised
detection and typing tools of the type reported here, refer-
ence laboratories will be able to detect the emergence of
potentially hypervirulent STEC clones and monitor their
spread.
Methods
Bacterial strains
All 73 E. coli O157 strains of human origin submitted to
the relevant microbiology reference laboratories in Argen-
tina, Australia and New Zealand between 1993 and 1996
were studied. Each strain represented a single isolate from
a particular patient and none was associated with a recog-
nised outbreak. The 35 Argentinian strains were submit-
ted to the National Reference Laboratory by different
hospitals. The 20 Australian and 18 New Zealand strains
were submitted by various diagnostic laboratories in both
countries to the Department of Microbiology and Immu-
nology, University of Melbourne, for confirmation of
their identity and further characterisation. In keeping with
the guidelines of our human ethics committees, all strains
were coded to protect patient confidentiality. The distri-
bution of strains isolated from patients in Argentina, Aus-
tralia, and New Zealand by clinical presentation is shown
in Table 1.
Phenotypic and genotypic characteristics of isolates
All strains were confirmed to be E. coli O157 by biochem-
ical tests [22], and serotyping using somatic and flagellar
antisera obtained from the Instituto Nacional de Produc-
ción de Biológicos – ANLIS "Dr. Carlos G. Malbrán" [23].
The presence of stx1, stx2 and rfbO157 was determined by
means of a multiplex PCR [24]. The reference E. coli
strains, EDL933 O157:H7 (stx1, stx2), and non-pathogenic
E. coli ATCC 25922 were used as positive and negativeBMC Microbiology 2008, 8:46 http://www.biomedcentral.com/1471-2180/8/46
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controls, respectively. Enterohaemolysin production was
detected on sheep blood agar plates [25]. To determine
Stx production, bacterial supernatant and periplasmic cell
extracts were used in cytotoxicity assays on Vero cells [26]
using Stx1- and Stx2- specific monoclonal antibodies
(MAb 13C4 and BC5BB12, respectively) kindly provided
by Dr. N. A. Strockbine, Centers for Disease Control and
Prevention, Atlanta, GA, USA. Additional virulence mark-
ers were characterised by PCR. The intimin (eae) and ehxA
genes were detected by PCR [4,27]. The presence of the
fliCH7 gene was tested as described by Gannon et al. [28].
Subtyping of isolates
Genotyping of stx2 variants was done by RFLP analysis of
the B-subunit-encoding DNA fragments obtained by PCR
[29] and extended to include primers and restriction
enzymes as described by Pierard et al. [30]. The reference
E. coli strains 92–3580 O157:H7 (stx2vh-a) and 93–016
O113:H21 (stx2vh-b) were kindly provided by Dr. D.
Woodward, of the National Microbiology Laboratory,
Public Health Agency ofCanada, Winnipeg, Manitoba,
Canada. stx1 variants were identified by RFLP and PCR
[31]. Phage typing was performed by the method origi-
nally described by Ahmed et al. [32] and extended by Kha-
khria et al. [17]. The E. coli O157 typing phages used were
kindly provided by R. Ahmed, of the National Microbiol-
ogy Laboratory, Winnipeg, Manitoba, Canada. Macror-
estriction fragment analysis by PFGE was performed using
the 24-h PulseNet standardised PFGE protocol for E. coli
O157:H7 [33] with minor modifications. Restriction
digestion of DNA embedded in plugs was performed with
30 U of XbaI or BlnI (Promega Corp., Madison, WI, USA)
at 37°C overnight. The PulseNet size standard strain used
was Salmonella Braenderup H9812 (kindly provided by
the Centers for Disease Control, Atlanta, GA, USA). DNA
fragments were resolved in 1% pulsed-field SeaKem Gold
agarose (FMC Bioproducts, Rockland, ME, USA) in 0.5×
TBE buffer at 14°C. PFGE was performed using a CHEF
DR-III system (Bio-Rad Laboratories, Hercules, CA, USA),
using a linear pulse ramp of 2.2–54.2 sec with a run length
of 18 h and a constant voltage of 200 V. Images of gels
were obtained using a Gel Doc 2000 (Bio-Rad Laborato-
ries). Analysis of TIFF images was performed using the
BioNumerics software package (Applied Maths, Kortrijk,
Belgium) using the Dice coefficient and UPGMA to gener-
ate dendrograms with 1.5% tolerance values. The clonal
relationship analysis was confirmed visually.
Statistical analysis
Statistical analysis of data was performed using InStat ver-
sion 3.05 (GraphPad Software Inc., San Diego, CA, USA).
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